Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces that after nearly 17 years with the Company, including 14 years as Chief Financial Officer (CFO), Mr Nigel Baade, has advised of his intention to leave Starpharma in early 2023 to pursue new professional opportunities.

Starpharma has commenced an executive search process for a new CFO / Company Secretary. Mr Baade will assist the Company in the transition until March 2023, completing the half year financial results.

Dr Jackie Fairley, Starpharma CEO, commented: “Starpharma’s Board and I would like to sincerely thank Nigel for his significant contribution and dedication over almost 17 years. Nigel is a highly regarded colleague who has played an important role across our business. On behalf of all at Starpharma, I would like to thank Nigel for his support and wish him every success in his future endeavours.”

Mr Nigel Baade said: “I thank Jackie, the Board and the entire team at Starpharma for the trust and support over the past 17 years, and I am proud of the achievements Starpharma has made over this time. The time is right for a new challenge, but I remain an advocate for the possibilities and opportunities for Starpharma’s dendrimer technology.”

View/Download ASX Announcement: Resignation of CFO / Company Secretary